Two-Drug combo targets Hard-to-Treat ovarian cancer
Disease control
Recruiting now
This phase 2 trial tests whether combining two oral drugs—ZEN003694 (a BET inhibitor) and talazoparib (a PARP inhibitor)—can shrink tumors in people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Participants must have already received a PARP inhibitor befo…
Phase: PHASE2 • Sponsor: Alexander B Olawaiye, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC